Published in Front Oncol on September 17, 2013
Unfixed endogenous retroviral insertions in the human population. J Virol (2014) 1.23
The decline of human endogenous retroviruses: extinction and survival. Retrovirology (2015) 0.81
Impacts of endogenous retroviruses on tumorigenesis, immunity, stem cells, and research safety. Front Oncol (2014) 0.76
Making a virtue of necessity: the pleiotropic role of human endogenous retroviruses in cancer. Philos Trans R Soc Lond B Biol Sci (2017) 0.76
Expression of evolutionarily novel genes in tumors. Infect Agent Cancer (2016) 0.75
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat Genet (1998) 7.49
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Methylation matters. J Med Genet (2001) 3.00
Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. Curr Biol (1999) 2.55
An almost-intact human endogenous retrovirus K on human chromosome 7. Nat Genet (1999) 1.87
An endogenous retrovirus derived from human melanoma cells. Cancer Res (2003) 1.76
CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2). J Virol (2005) 1.72
Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J Virol (1995) 1.72
Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res (2005) 1.65
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest (2008) 1.58
A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res (2002) 1.51
Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer (2007) 1.48
Quantitation of HERV-K env gene expression and splicing in human breast cancer. Oncogene (2003) 1.41
Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. Cancer Res (2008) 1.41
Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst (2012) 1.30
Genomic organization of the human endogenous retrovirus HERV-K(HML-2.HOM) (ERVK6) on chromosome 7. Genomics (2001) 1.28
The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. Exp Cell Res (2009) 1.27
Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer (2009) 1.24
Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker. Neoplasia (2008) 1.24
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med (2012) 1.23
Detecting the expression of human endogenous retrovirus E envelope transcripts in human prostate adenocarcinoma. Cancer (2003) 1.23
L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol Cancer (2004) 1.20
Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements. Gene (2009) 1.19
Expression of melanocyte-related genes in human breast cancer and its implications. Differentiation (2009) 1.13
Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. AIDS Res Hum Retroviruses (2008) 1.11
Specificity of antibodies directed against Env protein of human endogenous retroviruses in patients with germ cell tumors. Cancer Res (1996) 1.08
Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation. Genes Chromosomes Cancer (2010) 1.07
Regulation of human endogenous retrovirus-K Gag expression in teratocarcinoma cell lines and human tumours. J Gen Virol (1996) 1.00
Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS Res Hum Retroviruses (2006) 0.99
Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood (2002) 0.99
Expression of an endogenous retroviral sequence from the HERV-H group in gastrointestinal cancers. Int J Cancer (2007) 0.97
Expression of the human endogenous retrovirus HTDV/HERV-K is enhanced by cellular transcription factor YY1. J Virol (1999) 0.96
Expression of the human endogenous retrovirus (HERV) group HML-2/HERV-K does not depend on canonical promoter elements but is regulated by transcription factors Sp1 and Sp3. J Virol (2011) 0.93
Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses. Cancer Res (2006) 0.92
The long terminal repeats of the HERV-H human endogenous retrovirus contain binding sites for transcriptional regulation by the Myb protein. J Gen Virol (1999) 0.91
Expression of Human Endogenous Retrovirus Type K Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer. Genes Cancer (2011) 0.89
Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. Oncogene (2011) 0.85
Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes. Cancer Immunol Immunother (2011) 0.84
Activation of the long terminal repeat of human endogenous retrovirus K by melanoma-specific transcription factor MITF-M. Neoplasia (2011) 0.83
Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell (2009) 8.62
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med (2009) 4.59
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol (2006) 1.88
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest (2008) 1.58
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res (2004) 1.42
Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood (2004) 1.39
Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant (2007) 1.31
Cell labeling for magnetic resonance imaging with the T1 agent manganese chloride. NMR Biomed (2006) 1.30
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood (2008) 1.28
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med (2012) 1.23
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood (2004) 1.23
Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol (2006) 1.23
Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.21
Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion (2002) 1.13
In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood (2003) 1.12
Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis (2003) 1.10
Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells. J Cancer (2011) 1.07
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp Hematol (2007) 1.04
Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. Blood (2010) 1.03
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res (2004) 1.02
Hematopoietic cell transplantation for benign hematological disorders and solid tumors. Hematology Am Soc Hematol Educ Program (2003) 0.93
Ex vivo expansion of retrovirally transduced primate CD34+ cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation. Mol Ther (2010) 0.89
What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma. Biol Blood Marrow Transplant (2007) 0.88
Persistence of recipient human leucocyte antigen (HLA) antibodies and production of donor HLA antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation. Br J Haematol (2014) 0.87
Fusarium proliferatum soft tissue infection at the site of a puncture by a plant: recovery, isolation, and direct molecular identification. J Clin Microbiol (2009) 0.86
Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol (2013) 0.86
Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. Biol Blood Marrow Transplant (2006) 0.83
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. Lancet Oncol (2005) 0.83
Mitochondrial DNA sequence heterogeneity of single CD34+ cells after nonmyeloablative allogeneic stem cell transplantation. Stem Cells (2007) 0.82
Prospective evaluation of cell kinetics, yields and donor experiences during a single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells. Br J Haematol (2003) 0.82
Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes. Am J Hematol (2013) 0.82
Absence of donor-derived keratinocyte stem cells in skin tissues cultured from patients after mobilized peripheral blood hematopoietic stem cell transplantation. Exp Hematol (2002) 0.81
Severe Meningoencephalitis in a Case of Ebola Virus Disease: A Case Report. Ann Intern Med (2016) 0.81
Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis. Biol Blood Marrow Transplant (2007) 0.81
High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcoma. Biol Blood Marrow Transplant (2009) 0.80
Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease. Cytotherapy (2009) 0.78
Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma. Clin Cancer Res (2004) 0.78
Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy. Expert Rev Anticancer Ther (2004) 0.77
Topical tacrolimus with custom trays in the treatment of severe oral chronic graft-versus-host disease refractory to a potent topical steroid therapy: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 0.76
Allogeneic hematopoetic stem cell transplantation for cytokine refractory renal cell carcinoma. Cancer Treat Res (2003) 0.76
Early Diagnosis of Labial Fusion in Women After Allogeneic Hematopoietic Cell Transplant Enables Outpatient Treatment. J Low Genit Tract Dis (2016) 0.75
Cytotoxins and cancer immunotherapy: the dance of the macabre? J Natl Cancer Inst (2005) 0.75
Positron emission tomography for lymphoma staging: tissue remains the issue. J Natl Cancer Inst (2005) 0.75
4th Edition of the International Autologous and Allogeneic Cell Therapy for Solid Tumors (ATST) Meeting. J Cancer (2011) 0.75
Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement. Urol Clin North Am (2003) 0.75
Haploidentical, non-myeloablative stem-cell transplantation for advanced renal-cell carcinoma. Lancet Oncol (2004) 0.75